Analyst Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics and keeping the price target at $25.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Francois Brisebois has given his Buy rating due to a combination of factors, including Larimar Therapeutics’ steady clinical and regulatory progress for nomlabofusp and a clear path toward an accelerated approval strategy. The company remains on schedule to deliver key topline data in Q2 2026, initiate a rolling BLA in June 2026, and submit final CMC-related modules in the second half of 2026, supporting a potential U.S. launch in the first half of 2027, while the price target is unchanged at $25.
In addition, regulatory interactions have validated the use of frataxin as a novel surrogate endpoint and supported the exposure–response framework that could underpin the BLA, reducing perceived regulatory risk. Brisebois also highlights that safety concerns, including anaphylaxis, appear controllable with mitigation protocols, and that Larimar’s cash position of about $200 million provides funding into Q2 2027, comfortably beyond major clinical and regulatory milestones and reinforcing the Buy thesis.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $12.00 price target.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LRMR in relation to earlier this year.